Diasome key facts
- Developer of novel and cell-targeted therapies designed to treat diabetes, obesity, and other metabolic conditions.
- It has raised $89.7M; the latest was Later Stage VC ($3.1M) in Aug 2024.
- Notable investors include Eli Lilly and Company Foundation, Devon Park Bioventures, Endo Investors, McDonald Partners, Medicxi — 6 tracked in total.
- Status: Privately Held (backing).
- ·Watch Diasome: the Monday email on marks, rounds and moves
Diasome funding rounds
No funding rounds for Diasome are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Diasome investors
6 investors are on record for Diasome, including Eli Lilly and Company Foundation, Devon Park Bioventures, Endo Investors and McDonald Partners.
About Diasome
Developer of novel and cell-targeted therapies designed to treat diabetes, obesity, and other metabolic conditions. The company's therapies leverage technology, an insulin additive, to lessen the instances of high and low blood sugar levels in people with diabetes, enabling patients to get novel proprietary liver-targeted insulins for both Type one and Type two diabetes easily.
- Sector
- Healthcare
- HQ
- Cleveland, OH, United States
- Founded
- 2004
- Employees
- 10
- Website
- diasome.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Diasome doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.